Advanced Search

 

Study ID Status Title Patient Level Data
201315 Completed A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Glycopyrronium 44 mcg in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
201316 Completed A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
201379 Active not recruiting Patterns of Care for Patients with Metastatic Renal Cell Carcinoma in a United States Population
201426 Completed PRJ2250: Survey of patient and prescriber understanding of risks associated with TROBALT
201474 Completed A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Mometasone Furoate Nasal Spray in Subjects with Allergic Rhinitis
201529 Completed Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil from Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated Co. to GalaxoSmithKline ) and Biodroxil 1 gm Film Coated tablets (Kahira Pharm &Chem .Ind. Co. for Novartis Pharma ) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions Study Listed on ClinicalStudyDataRequest.com
201761 Completed PGx7610: Genetic Evaluation of Hepatotoxicity in Pazopanib Studies
201909 Completed An open-label study investigating critical and overall errors following 14 days of treatment with SERETIDE Metered Dose Inhaler (EVOHALER) in adult subjects with controlled asthma currently using the SERETIDE DISKUS Inhaler
201959 Completed A Phase III study for the evaluation of the immunogenicity and reactogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 season Southern Hemisphere) in adults 18 years of age and above
207499/040 Completed A Multicentre, Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral SB-207499 (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/041 Completed A Multicenter Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Cilomilast (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/125 Completed A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding a New Chemical Entity (NCE) to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/156 Completed A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD). Study Listed on ClinicalStudyDataRequest.com
207499/157 Completed A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Oral Cilomilast (15 mg bd) When Given as Maintenance Treatment for 12 Months to Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/168 Completed A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Cilomilast 15mg Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
207499/180 Completed An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated patients with stable COPD Study Listed on ClinicalStudyDataRequest.com
207499/181 Completed A 13-week randomised, double-blind, parallel group, mulitcentre study to compare the bronchial anti-inflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
208108/059 Completed A post-marketing surveillance study of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b (Hib) tetanus conjugate vaccine in 3,000 Filipino subjects. Study Listed on ClinicalStudyDataRequest.com
208108/087 Completed Phase 2 open randomized primary vaccination study to assess the immunogenicity and reactogenicity of GSK Biologicals' Haemophilus influenzae type b conjugate vaccine administered with commercially available DTPw vaccine as compared to GSK Biologicals' Hib administered mixed with GSK Biologicals' DTPw vaccine in healthy infants Study Listed on ClinicalStudyDataRequest.com
208108/091 Completed A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects Study Listed on ClinicalStudyDataRequest.com
208108-083 Completed A phase IV, open, multicentric, post-marketing surveillance study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ Haemophilus influenzae type b vaccine (Hiberix™) in Korean subjects administered according to the Prescribing Information. Study Listed on ClinicalStudyDataRequest.com
208109/210 Completed A Phase 4, open, comparative, multicenter study of the immunogenicity and safety of SmithKline Beecham Biologicals' inactivated hepatitis A vaccine (Havrix) 720 EL.U/ 0.5 ml on a 0, 6-month schedule, administered by intramuscular injection, either to children aged (1) 15 to 18 months old or (2) 11 to 13 months old, when compared to 23 to 25 month-old children; and to determine the immune responses following co-administration of routine childhood vaccines, DTPa and Hib in the 15 to 18 month age g Study Listed on ClinicalStudyDataRequest.com
208109/220 Completed A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GSK Biologicals' inactivated hepatitis A vaccine administered on a 0-6 mth schedule concomitantly with Wyeth Lederle's pneumococcal conjugate vaccine in healthy children 15 months of age Study Listed on ClinicalStudyDataRequest.com
208109/228 Completed A phase IV open study to assess the anamnestic response to a single intramuscular injection of GSK Biologicals’ hepatitis A vaccine, Havrix™ Junior in healthy adult subjects who have had a previously documented seropositive status following a full course of primary vaccination with GSK Biologicals’ hepatitis A vaccine Study Listed on ClinicalStudyDataRequest.com
208109/229 Completed A Phase IIIb, open, multicenter study of the immunogenicity and safety of one dose of GSK Biologicals' inactivated hepatitis A vaccine administered to healthy children who were seropositive for anti-HAV Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.